NeuroSense Therapeutics and NeuraLight Collaborate to Detect ALS Oculometric Biomarkers

NeuraLight is on a mission to transform the lives of billions of people impacted by neurological disorders by digitizing neurological evaluation and care. Using their AI-driven platform to integrate multiple digital markers to accelerate and improve drug development, monitoring, and precision care for patients with neurological disorders, NeuraLight is revolutionizing patient care. NeuraLight's platform, which uses proprietary computer vision and deep learning algorithms to extract over 100 occulometic markers from facial videos captured with a standard webcam, will be used to evaluate ALS patients in a study parallel to NeuroSense's Phase IIb PARADIGM trial. PARADIGM is a double-blind, placebo-controlled study evaluating the efficacy of NeuroSense's lead combination drug candidate, PrimeC, in the treatment of ALS. The NeuroSense-NeuraLight collaboration entails sharing and tracking patient data to advance the identification and use of ALS digital biomarkers.